Oxford Immune Algorithmics, growing by leaps and bounds, recently announced the appointment of Mr. Tony Cambridge to its Scientific Advisory Board.
Mr. Tony Cambridge has an MSc. in Biomedical Sciences from the University of Plymouth. Heis Managing Director of Thornhill Healthcare Events and Consultancy and Lead Biomedical Scientist on the Pathology Management team of a busy acute care hospital in England. He is a frequent speaker at national and international healthcare events and is a thought-leader for point-of-care testing. Mr. Cambridge is active across healthcare platforms, offering advice and guidance, and is a member of a global diagnostics company’s scientific advisory committee.
In addition, Mr. Cambridge co-authored the British Society of Haematology’s point-of-care testing guidelines for general haematology. His company organises educational events and recently launched a website, www.POCTInnovators.com, to champion point of care, rapid and decentralised diagnostics. The website is free and open-access and was conceived as a resource for healthcare professionals, diagnostics companies, and key opinion leaders to share information related to point-of-care, rapid and decentralised diagnostics. It serves as a one-stop-shop for information on the healthcare sector and health technology and delivers critical support to adopters of essential solutions in optimising patient care, promoting understanding and driving health excellence.
Oxford Immune Algorithmics warmly welcomes Tony Cambridge to its Scientific Advisory Board as it liberates individual healthcare through early disease detection and effective health management.
Oxford Immune Algorithmics (OIA) is an award-winning Bio-Tech company incubated by the University of Oxford with a vision to democratise healthcare to rid the world of preventable diseases. To do this, OIA harnesses the power of an advanced type of augmented AI that has human-like reasoning capabilities to monitor people’s immune systems. OIA operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.